Not Yet RecruitingNot Applicable

Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation for T-Lymphoblastic Leukemia/Lymphoma in First Complete Remission: A Prospective, Multicenter Cohort Study

84 participantsStarted 2026-05-05

Plain-language summary

To evaluate, through a prospective multicenter observational study, autologous or allogeneic hematopoietic stem cell transplantation as consolidation therapy in subjects with T-ALL/LBL who have achieved first complete remission (CR). Assess relapse-free survival (RFS), overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM) among different treatment regimens

Who can participate

Age range14 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Creatinine clearance (by Cockcroft-Gault formula) ≥60 mL/min
✓. Cardiac ejection fraction \>50%, with no clinically significant ECG abnormalities
✓. Baseline oxygen saturation \>92%
✓. Total bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN Ability to understand the trial and signed informed consent

What they're measuring

Relapse free survival

Timeframe: 24 months

Trial details

NCT IDNCT07577531

SponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-05-05

Contact for this trial

Xianmin Song

021-36123559 shongxm@sjtu.edu.cn

View on ClinicalTrials.gov More T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma trials